Clinical Trials in Lemon Grove, California

21 recruiting

Showing 120 of 21 trials

Recruiting
Phase 3

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

Schizophrenia
LB Pharmaceuticals Inc.456 enrolled13 locationsNCT07363577
Recruiting
Phase 2

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Bipolar 1 Disorder
Rapport Therapeutics Inc.224 enrolled22 locationsNCT07046494
Recruiting
Phase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 2

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics500 enrolled5 locationsNCT07459647
Recruiting
Phase 3

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences560 enrolled17 locationsNCT07227818
Recruiting
Phase 3

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

Schizophrenia
Neurocrine Biosciences800 enrolled53 locationsNCT07114874
Recruiting
Phase 2

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

Bipolar I or II Disorder
AbbVie200 enrolled49 locationsNCT07220460
Recruiting
Phase 2

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder
Sirtsei Pharmaceuticals, Inc.456 enrolled50 locationsNCT06254612
Recruiting
Phase 2

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Major Depressive Disorder
AbbVie195 enrolled31 locationsNCT07276997
Recruiting
Phase 3

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company280 enrolled175 locationsNCT05304767
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics300 enrolled25 locationsNCT07038876
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Major Depressive Disorder (MDD)
Vanda Pharmaceuticals500 enrolled38 locationsNCT06830044
Recruiting
Phase 2

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Alzheimer Disease
Alzheimer's Disease Cooperative Study (ADCS)406 enrolled47 locationsNCT06223360
Recruiting
Phase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight Loss
Viking Therapeutics, Inc.1,100 enrolled134 locationsNCT07104383
Recruiting
Phase 2

Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder

Generalized Anxiety Disorder (GAD)
AbbVie315 enrolled52 locationsNCT06846320
Recruiting
Phase 3

Randomized Withdrawal Study in Patients With Schizophrenia

Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968
Recruiting
Phase 2

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

Generalized Anxiety Disorder
Intra-Cellular Therapies, Inc.705 enrolled69 locationsNCT06480383
Recruiting
Phase 2

A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia

Cognitive Impairment Associated With Schizophrenia (CIAS)
Kynexis B.V.150 enrolled13 locationsNCT07191483
Recruiting
Phase 3

Study of Lumateperone in the Acute Treatment of Patients With Bipolar Mania

Bipolar Disorder, Manic
Intra-Cellular Therapies, Inc.350 enrolled42 locationsNCT06462586
Recruiting

Assessment of Methadone Dose Taken

Pain, ChronicDrug Metabolism, Poor, CYP2D6-RelatedMethadone Toxicity+2 more
Cari Health Inc.30 enrolled1 locationNCT05981573